Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Gen Surg SAQsendocrine

Gen Surg SAQs · endocrine

Small pancreatic tumour verdicts, insulinoma localisation ladders, and gastrinoma cure operations

Fellowship SAQ on small pancreatic NET surveillance-versus-resection verdicts with node-risk scoring, insulinoma localisation and parenchyma-sparing ladders, and gastrinoma duodenotomy cure operations.

10 marks12 min1 min readVerification in progress

Target exams

FRACSFRCS(Gen Surg)ABSFRCSC
On this page
Study tools

Target exams

FRACSFRCS(Gen Surg)ABSFRCSC
Prompt
A 34-year-old woman has a 1.4 cm distal nonfunctioning pancreatic neuroendocrine tumour with low proliferation, a 41-year-old man has Whipple triad with a localised insulinoma, and a 52-year-old man has sporadic Zollinger-Ellison syndrome with a duodenal primary and liver-free imaging. (A) Judge the small pancreatic lesion: surveillance versus resection with size, database and node-risk numbers. (4 marks) (B) Localise and resect the insulinoma with sensitivity and approach arithmetic. (3 marks) (C) Plan the gastrinoma cure operation with duodenotomy gains, expected cure fractions and procedure choice. (3 marks)

Write your answer

Saved on this device. No marking — you are the marker.

(A) Surgery is default above one centimetre and selective below it: pooled pancreatic analysis gives operative mortality hazard 0.30 with 5-year survival 77% against 46%, yet sub-centimetre disease shows comparable survival either way.[10] Surveillance is defensible for the small asymptomatic lesion — five-study review at 540 patients with up to half showing growth, one in seven crossing to resection, and zero disease-related deaths on watch.[11] The database sharpens it: 2,004 localised well-differentiated tumours with resection improving survival above one centimetre, and age, comorbidity, stage, location and resection as independent prognostics.[12] Score her nodes before watching: the 1-to-7 location-plus-proliferation score bands low, intermediate and high risk — distal low-proliferation watches, proximal higher-proliferation resects with nodes.[13]

(B) Expect a 10-month median symptom-to-diagnosis delay, then localise with everything: CT, MRI and endoscopic ultrasound combined, ultrasound most sensitive with MRI and ultrasound each rescuing CT-negative tumours; spare parenchyma in suitable cases with formal resection for vessel, duct or malignancy concern.[16] Approach it minimally invasively when localised and feasible: 71-patient enucleation comparison with shorter minimally invasive times excluding conversions, equivalent late complications, 5.6% functional recurrence at 75 months, and no disease recurrence after R1 resection.[15]

(C) Open every sporadic duodenum: routine duodenotomy finds gastrinoma in 98% against 76% with duodenal primaries at 62% against 18%, lifting immediate cure to 65% against 44% and long-term cure to 52% against 26%.[17] Counsel honestly from the 10-year protocol: 78% found and resected, 11% morbidity without deaths, half the disease-free recurring by five years, yet excellent overall survival against 20% once metastatic at presentation — most found, about one-third cured.[18]

References8ShowHide
  1. [10]Khajeh E, et al. Surgical Versus Nonsurgical Management of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. Ann Surg Oncol, 2025.PMID 40705264
  2. [11]Partelli S, et al. Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. Br J Surg, 2017.PMID 27706803
  3. [12]Assi HA, et al. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database. Oncologist, 2020.PMID 32043766
  4. [13]Lopez-Aguiar AG, et al. The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management. Surgery, 2019.PMID 31072670
  5. [15]Belfiori G, et al. Minimally Invasive Versus Open Treatment for Benign Sporadic Insulinoma Comparison of Short-Term and Long-Term Outcomes. World J Surg, 2018.PMID 29691623
  6. [16]Andreasi V, et al. Diagnostic work-up and surgical management of insulinoma: A retrospective analysis from a tertiary referral center. J Neuroendocrinol, 2023.PMID 37915303
  7. [17]Norton JA, et al. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg, 2004.PMID 15082965
  8. [18]Norton JA, et al. Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study. Ann Surg, 1992.PMID 1531004
PreviousImaging verdicts with washout traps, blockade arithmetic, and Conn cure counsellingendocrineNextStorm resuscitation sequences, operating through thyrotoxicosis, and haematoma vigilance arithmeticendocrine